James B Breitmeyer insider trades: Oncternal Therapeutics (ONCT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 14, 2023 | ONCT | ↑ Buy | 150,000 | $0.29 | $44K | By Family Trust | Apr 17, 2023 (3d) |
| Jan 27, 2022 | ONCT | ↑ Buy | 25,000 | $1.68 | $42K | By Family Trust | Jan 31, 2022 (4d) |
| Dec 16, 2019 | ZGNX | ↓ Sell | 5,000 | $50.00 | $250K | Direct | Dec 18, 2019 (2d) |
| Nov 25, 2019 | ZGNX | ↓ Sell | 5,000 | $50.00 | $250K | Direct | Nov 27, 2019 (2d) |
| Nov 3, 2011 | CADX | ↓ Sell | 12,500 | $5.70 | $71K | Direct | Nov 4, 2011 (1d) |
| Jul 11, 2011 | CADX | ↓ Sell | 3,000 | $8.99 | $27K | Direct | Jul 12, 2011 (1d) |
| May 2, 2011 | CADX | ↓ Sell | 12,000 | $8.35 | $100K | Direct | May 3, 2011 (1d) |
| Apr 1, 2011 | CADX | ↓ Sell | 7,000 | $9.20 | $64K | Direct | Apr 5, 2011 (4d) |
| Mar 4, 2011 | CADX | ↓ Sell | 7,000 | $8.50 | $60K | Direct | Mar 8, 2011 (4d) |
| Feb 3, 2011 | CADX | ↓ Sell | 39,000 | $7.38 | $288K | Direct | Feb 4, 2011 (1d) |
| Nov 2, 2010 | CADX | ↓ Sell | 25,000 | $9.03 | $226K | Direct | Nov 3, 2010 (1d) |
| Oct 5, 2010 | CADX | ↓ Sell | 7,000 | $8.50 | $60K | Direct | Oct 6, 2010 (1d) |
| Sep 29, 2010 | CADX | ↓ Sell | 7,000 | $8.50 | $60K | Direct | Sep 29, 2010 (0d) |
| Apr 19, 2010 | CADX | ↓ Sell | 1,000 | $10.00 | $10K | Direct | Apr 20, 2010 (1d) |
| Feb 1, 2010 | CADX | ↓ Sell | 1,000 | $10.00 | $10K | Direct | Feb 2, 2010 (1d) |
| Jan 5, 2010 | CADX | ↓ Sell | 1,000 | $10.00 | $10K | Direct | Jan 6, 2010 (1d) |
| Dec 17, 2009 | CADX | ↓ Sell | 1,000 | $10.00 | $10K | Direct | Dec 18, 2009 (1d) |
| Nov 5, 2009 | CADX | ↓ Sell | 1,000 | $10.00 | $10K | Direct | Nov 6, 2009 (1d) |
| Oct 1, 2009 | CADX | ↓ Sell | 1,000 | $10.96 | $11K | Direct | Oct 2, 2009 (1d) |
| Sep 1, 2009 | CADX | ↓ Sell | 1,000 | $10.81 | $11K | Direct | Sep 2, 2009 (1d) |
| Aug 3, 2009 | CADX | ↓ Sell | 1,000 | $12.11 | $12K | Direct | Aug 5, 2009 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About James B Breitmeyer's insider trades
James B Breitmeyer is Chief Executive Officer at Oncternal Therapeutics (ONCT). Since Aug 3, 2009, James has reported 2 open-market purchases worth $86K and 19 sales worth $1.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (40 filings), option exercises (19 filings), shares withheld for taxes (3 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONCT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.